株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アミロイドーシス:パイプライン製品の分析

Amyloidosis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192465
出版日 ページ情報 英文 157 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
アミロイドーシス:パイプライン製品の分析 Amyloidosis - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 157 Pages
概要

アミロイドーシスとして知られる疾患群は、アミロイドタンパク質が体内の組織に異常に蓄積することから生じます。臓器の形状や機能に影響を与えるため、最終的に臓器不全に至ることもあります。素因として、L鎖と呼ばれる異常タンパク質のミスフォールディング、それに続く体内での蓄積が挙げられます。透析の結果、生じる場合もあります。症状は、倦怠感、胸痛、腫脹、呼吸障害などが見られます。治療には、移植、投薬 (利尿薬、化学療法薬) などが含まれます。

当レポートでは、アミロイドーシスに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

アミロイドーシスの概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • ProteoTech, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALN-TTRsc02
  • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
  • carfilzomib
  • CLR-01
  • eprodisate disodium
  • GSK-2315698 + GSK-2398852
  • GSK-2398852
  • ixazomib citrate
  • LUNAR-101
  • LUNAR-102
  • Monoclonal Antibody for Amyloidosis
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
  • NEOD-001
  • NPT-005
  • patisiran
  • pomalidomide
  • PTI-110
  • revusiran
  • Small Molecules for AL Amyloidosis
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
  • tafamidis meglumine
  • tolcapone

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9562IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Amyloidosis - Overview
    • Amyloidosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Amyloidosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Amyloidosis - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Amgen Inc
    • Arcturus Therapeutics Inc
    • Bsim2
    • Celgene Corp
    • GlaxoSmithKline Plc
    • Ionis Pharmaceuticals Inc
    • Johnson & Johnson
    • Millennium Pharmaceuticals Inc
    • Neurimmune Holding AG
    • Novartis AG
    • Oncopeptides AB
    • Pfizer Inc
    • Prothena Corp Plc
    • R Pharm
    • Regeneron Pharmaceuticals Inc
    • SOM Biotech SL
    • Spectrum Pharmaceuticals Inc
  • Amyloidosis - Drug Profiles
    • AG-10 - Drug Profile
    • ALN-ANG - Drug Profile
    • ALN-TTRsc02 - Drug Profile
    • CAEL-101 - Drug Profile
    • canakinumab - Drug Profile
    • carfilzomib - Drug Profile
    • CLR-01 - Drug Profile
    • daratumumab - Drug Profile
    • dezamizumab - Drug Profile
    • dezamizumab + GSK-2315698 - Drug Profile
    • doxycycline hyclate - Drug Profile
    • EDE-1307 - Drug Profile
    • GSK-2315698 - Drug Profile
    • GSK-3039294 - Drug Profile
    • inotersen sodium - Drug Profile
    • ixazomib citrate - Drug Profile
    • LUNAR-TTR - Drug Profile
    • melphalan - Drug Profile
    • melphalan flufenamide - Drug Profile
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
    • Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
    • NEOD-001 - Drug Profile
    • NI-301 - Drug Profile
    • NPT-289 - Drug Profile
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
    • patisiran - Drug Profile
    • pomalidomide - Drug Profile
    • PRX-004 - Drug Profile
    • RPH-104 - Drug Profile
    • Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile
    • Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
    • tafamidis meglumine - Drug Profile
    • tolcapone - Drug Profile
  • Amyloidosis - Dormant Projects
  • Amyloidosis - Discontinued Products
  • Amyloidosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Amyloidosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Amyloidosis - Pipeline by Amgen Inc, H2 2017
  • Amyloidosis - Pipeline by Arcturus Therapeutics Inc, H2 2017
  • Amyloidosis - Pipeline by Bsim2, H2 2017
  • Amyloidosis - Pipeline by Celgene Corp, H2 2017
  • Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Amyloidosis - Pipeline by Johnson & Johnson, H2 2017
  • Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2017
  • Amyloidosis - Pipeline by Novartis AG, H2 2017
  • Amyloidosis - Pipeline by Oncopeptides AB, H2 2017
  • Amyloidosis - Pipeline by Pfizer Inc, H2 2017
  • Amyloidosis - Pipeline by Prothena Corp Plc, H2 2017
  • Amyloidosis - Pipeline by R Pharm, H2 2017
  • Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Amyloidosis - Pipeline by SOM Biotech SL, H2 2017
  • Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
  • Amyloidosis - Dormant Projects, H2 2017
  • Amyloidosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Amyloidosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top